Antineoplastic Combined Chemotherapy Protocols
"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
| Descriptor ID |
D000971
|
| MeSH Number(s) |
E02.183.750.500 E02.319.077.500 E02.319.310.037
|
| Concept/Terms |
Antineoplastic Combined Chemotherapy Protocols- Antineoplastic Combined Chemotherapy Protocols
- Combined Antineoplastic Agents
- Antineoplastic Agents, Combined
- Agent, Combined Antineoplastic
- Agents, Combined Antineoplastic
- Antineoplastic Agent, Combined
- Combined Antineoplastic Agent
- Antineoplastic Combined Chemotherapy Regimens
- Drug Combinations, Antineoplastic
- Anticancer Drug Combinations
- Anticancer Drug Combination
- Drug Combination, Anticancer
- Drug Combinations, Anticancer
- Antineoplastic Drug Combinations
- Antineoplastic Drug Combination
- Combinations, Antineoplastic Drug
- Drug Combination, Antineoplastic
Antineoplastic Chemotherapy Protocols- Antineoplastic Chemotherapy Protocols
- Antineoplastic Chemotherapy Protocol
- Chemotherapy Protocol, Antineoplastic
- Protocol, Antineoplastic Chemotherapy
- Protocols, Antineoplastic Chemotherapy
- Cancer Chemotherapy Protocols
- Cancer Chemotherapy Protocol
- Chemotherapy Protocol, Cancer
- Chemotherapy Protocols, Cancer
- Protocol, Cancer Chemotherapy
- Protocols, Cancer Chemotherapy
- Chemotherapy Protocols, Antineoplastic
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".
This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in this website by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 6 | 2 | 8 |
| 1997 | 7 | 1 | 8 |
| 1998 | 11 | 3 | 14 |
| 1999 | 7 | 1 | 8 |
| 2000 | 9 | 3 | 12 |
| 2001 | 5 | 3 | 8 |
| 2002 | 9 | 7 | 16 |
| 2003 | 8 | 8 | 16 |
| 2004 | 6 | 7 | 13 |
| 2005 | 13 | 5 | 18 |
| 2006 | 13 | 4 | 17 |
| 2007 | 12 | 4 | 16 |
| 2008 | 23 | 8 | 31 |
| 2009 | 21 | 8 | 29 |
| 2010 | 20 | 12 | 32 |
| 2011 | 19 | 15 | 34 |
| 2012 | 20 | 5 | 25 |
| 2013 | 21 | 6 | 27 |
| 2014 | 33 | 13 | 46 |
| 2015 | 28 | 12 | 40 |
| 2016 | 13 | 21 | 34 |
| 2017 | 27 | 19 | 46 |
| 2018 | 41 | 15 | 56 |
| 2019 | 38 | 14 | 52 |
| 2020 | 29 | 23 | 52 |
| 2021 | 16 | 36 | 52 |
| 2022 | 9 | 45 | 54 |
| 2023 | 6 | 42 | 48 |
| 2024 | 23 | 21 | 44 |
| 2025 | 33 | 7 | 40 |
| 2026 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
Maintaining oxaliplatin therapy after hypersensitivity reactions: real-world experience with a desensitisation protocol. Clin Exp Med. 2026 Jan 21; 26(1):118.
-
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial. Nat Med. 2026 Mar; 32(3):992-1001.
-
Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma. Blood Adv. 2026 Jan 13; 10(1):183-191.
-
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial. Clin Cancer Res. 2026 Jan 06; 32(1):214-223.
-
BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML. Leukemia. 2026 Feb; 40(2):304-313.
-
Cutaneous Melanoma: A Review. JAMA. 2025 Dec 16; 334(23):2113-2125.
-
FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML. Blood. 2025 Nov 20; 146(21):2608-2611.
-
Overall Survival for Bevacizumab Therapy in Metastatic Colorectal Cancer: An Updated Analysis of the TRAVASTIN Study. Clin Colorectal Cancer. 2026 Mar; 25(1):115-124.
-
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2026 Feb 05; 394(6):551-562.
-
Prognostic relevance of the neutrophil/lymphocyte ratio in diffuse large B-cell lymphoma: a systematic review and meta-analysis and dose-response evidence. Leuk Lymphoma. 2025 Dec; 66(14):2752-2764.